This article was originally published in The Rose Sheet
Company has received all of the required lender consents to increase its existing $700 mil. term loan facility by $100 mil. under an amendment to its bank credit agreement dated 2004, Revlon announces July 24. Firm expects to close and fund the amendment July 28, "subject to market and other customary conditions," firm notes. Revlon announced it was seeking an amendment to the credit agreement earlier this month (1"The Rose Sheet" June 26, 2006, In Brief)...
You may also be interested in...
Revlon is renewing plans for Vital Radiance, focusing resources behind the brand's revised retail format, its most productive products and most effective marketing drivers, the company reported during a preliminary second quarter earnings call July 10
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.